| Budget Amount *help |
¥107,380,000 (Direct Cost: ¥82,600,000、Indirect Cost: ¥24,780,000)
Fiscal Year 2020: ¥20,930,000 (Direct Cost: ¥16,100,000、Indirect Cost: ¥4,830,000)
Fiscal Year 2019: ¥21,840,000 (Direct Cost: ¥16,800,000、Indirect Cost: ¥5,040,000)
Fiscal Year 2018: ¥21,840,000 (Direct Cost: ¥16,800,000、Indirect Cost: ¥5,040,000)
Fiscal Year 2017: ¥21,840,000 (Direct Cost: ¥16,800,000、Indirect Cost: ¥5,040,000)
Fiscal Year 2016: ¥20,930,000 (Direct Cost: ¥16,100,000、Indirect Cost: ¥4,830,000)
|
|---|
| Outline of Final Research Achievements |
We have created a 20,000-species human protein array (20K-HUPA) that covers almost all human proteins based on our originally developed wheat cell-free protein synthesis system, and have been studying (1) the development of large-scale analytical interaction analysis technology using 20K-HUPA, (2) the development of NF-κB signaling inhibitors, (3) the (3) Elucidation and mathematical simulation of the response control mechanism of the plant hormone gibberellin, (4) Elucidation of the TGF-β signaling mechanism via SMAD3, which is ubiquitinated by MIB2, (5) Creation of a novel proximal-dependent biotinyltransferase, and (6) Construction of a proteolysis-inducing molecular analysis technology using thalidomide as a model. (5) creation of a novel proximal-dependent biotinyltransferase, and (6) construction of a molecular analysis technique to induce protein degradation using thalidomide as a model.
|
